
Shares of Johnson & Johnson JNJ.N rise 0.3% to $244.40 after the company said it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania
JNJ is on track to snap two straight sessions of losses
The investment is part of its larger plans announced last year to scale up U.S. manufacturing amid President Donald Trump's tariff threats
In March, the company announced a plan to invest more than $55 billion through early 2029 to build manufacturing facilities and the research infrastructure in the U.S.
Other major drugmakers, including Eli Lilly LLY.N and AstraZeneca AZN.L, have also committed billions of dollars in investments to scale up their U.S. footprint in response to Trump's tariff threats
Among 28 analysts covering JNJ, avg rating is "buy" and the median PT is $237, per LSEG data
JNJ up 18% YTD vs S&P 500 health care index .SPXHC, which is up 1.3%